How to Get Rezdiffra (Resmetirom) in Hawaii
Rezdiffra (resmetirom) is a once-daily oral medication that selectively activates thyroid hormone receptor-beta (THR-β), manufactured by Madrigal Pharmaceuticals. The FDA granted resmetirom accelerated approval in March 2024 for use in adults with metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH) and moderate to advanced fibrosis (F2-F3 stages), as a complement to lifestyle modifications including diet and exercise. Resmetirom is not indicated for nonalcoholic fatty liver disease without fibrosis, nor is it classified as a weight-loss medication.
For most Hawaii residents, the practical bottleneck is not finding a prescriber. Hawaii permits telehealth prescribing of non-controlled medications, so a licensed physician, nurse practitioner, or physician assistant can evaluate and prescribe resmetirom without an in-person visit. The bottleneck is coverage: Rezdiffra is a specialty-tier drug that most commercial and Medicare Part D plans place behind prior authorization, and Hawaii Medicaid (Med-QUEST) has not added it to its preferred drug list as of this writing. That single coverage gap, more than distance or specialist availability, determines how quickly a Hawaii patient can actually take the first dose.
What is established, what is not
Established: Resmetirom has FDA approval for MASH with F2-F3 fibrosis, is taken as a daily tablet, requires baseline and periodic liver enzyme monitoring, and is contraindicated in decompensated cirrhosis. This is documented in the FDA-approved prescribing information for Rezdiffra.
Plausible but requiring plan-level verification: Typical prior authorization documentation, insurer turnaround times, specialty pharmacy shipping windows to Hawaii, and out-of-pocket cost after manufacturer assistance. These vary by plan and change over time; none of the figures below should be treated as fixed.
Not established from the sources reviewed for this page: Exact Hawaii statute citations governing telehealth and pharmacy licensure, the specific dollar amount of Rezdiffra's wholesale acquisition cost, and the exact number of Hawaii residents affected by the Medicaid coverage gap. These require direct verification against the Hawaii Department of Commerce and Consumer Affairs, the Hawaii Board of Pharmacy, and the payer in question before being cited to a patient.
Confirming the diagnosis before you look for a prescriber
The FDA label restricts Rezdiffra to MASH with fibrosis stage F2 or F3. Diagnosis and staging are established either by liver biopsy or by a noninvasive combination that a hepatologist or gastroenterologist interprets, commonly transient elastography (FibroScan) together with the FIB-4 index or a similar noninvasive fibrosis score. A prescriber cannot write a Rezdiffra prescription that will pass prior authorization without documentation of fibrosis stage; this is the single most common cause of delay described in the prescribing process, more so than any Hawaii-specific rule.
Before initiating treatment, the label requires baseline liver enzymes (ALT, AST, bilirubin) and specifies that treatment should not start if ALT or AST exceeds five times the upper limit of normal. A baseline lipid panel is also recommended, because resmetirom's THR-β activity lowers LDL cholesterol, which matters for patients on concurrent statin therapy. Ongoing liver enzyme monitoring is recommended during treatment; the exact monitoring interval your prescriber chooses should follow the current FDA label and their own clinical judgment rather than a fixed schedule quoted online.
Who can prescribe it in Hawaii, and where
Resmetirom is not a controlled substance, so prescribing does not require DEA scheduling beyond a standard state medical or advanced-practice license. In general, physicians (MD/DO), nurse practitioners and other advanced practice registered nurses with prescriptive authority, and physician assistants working under a supervising physician can prescribe non-controlled specialty medications in Hawaii. The exact scope-of-practice rules and any recent legislative changes should be confirmed against the Hawaii Board of Nursing and Board of Medical Examiners, since these rules are periodically updated.
Hawaii allows telehealth to establish a valid patient-provider relationship for prescribing purposes, which is why both Hawaii-based and mainland telehealth services can see and treat Hawaii patients if the prescriber holds a Hawaii license (or is registered through Hawaii's out-of-state telehealth pathway, where applicable). A telehealth visit for Rezdiffra typically covers three things: history and risk factor review (obesity, type 2 diabetes, metabolic syndrome), review of existing imaging or biopsy results establishing fibrosis stage, and medication reconciliation, particularly checking concurrent statin dosing given resmetirom's LDL-lowering effect. Labs can usually be ordered electronically to a Hawaii-accessible lab and results reviewed at a follow-up virtual visit before the prescription is finalized. One scheduling detail worth planning around: Hawaii Standard Time (UTC-10) means a mainland telehealth provider's normal office hours may fall outside Hawaii daytime hours, so confirm appointment availability before enrolling.
Getting the prescription filled
Rezdiffra is distributed through a limited specialty pharmacy network rather than every retail pharmacy, which is standard for newly approved specialty drugs. Your insurer will typically designate which specialty pharmacy is in-network; confirming this before the prescription is sent avoids a rejected fill. Shipping a tablet formulation to Hawaii does not require cold-chain handling, which simplifies logistics compared with many injectable specialty drugs, but neighbor-island addresses may still see longer transit times than Oahu addresses.
503A compounding pharmacies are licensed to operate in Hawaii and can compound patient-specific preparations under a valid prescription. This route is uncommon for resmetirom, which is commercially available as 80 mg and 100 mg tablets, and would only be relevant if a prescriber determines a non-standard dose or formulation is clinically necessary. Compounded resmetirom is not FDA-approved in that form; it is prepared under a prescriber's independent judgment and pharmacy compounding rules, and patients should understand that distinction before pursuing it.
Prior authorization: the real gatekeeper
Nearly all commercial insurers and Medicare Part D plans require prior authorization for Rezdiffra given its specialty pricing. A typical PA packet includes:
- Confirmed MASH diagnosis with documented fibrosis stage F2 or F3 (biopsy report, or FibroScan plus a validated noninvasive score)
- Baseline ALT/AST below five times the upper limit of normal
- Documentation of metabolic risk factors (BMI, HbA1c, lipid panel)
- Prescriber attestation that decompensated cirrhosis (Child-Pugh B or C) is absent, since this is a contraindication on the label
- In some plans, documentation that lifestyle intervention (diet, exercise, weight management) was attempted first
How long a specific insurer takes to decide, and whether it demands a peer-to-peer review before approving, varies by plan and changes over time. Rather than quote a specific turnaround window here, confirm current PA timelines directly with the plan's specialty pharmacy or utilization management department at the time of the request. If a PA is denied, Hawaii's insurance regulations provide for an internal appeal and, if that fails, an external review process for denied specialty drug claims; ask the prescriber's office to initiate a peer-to-peer review with the plan's medical director as a first step.
Hawaii Medicaid does not currently cover Rezdiffra
As of this writing, Hawaii Medicaid (Med-QUEST) has not added Rezdiffra to its preferred drug list. This is a coverage decision that can change, so anyone relying on Medicaid should ask their managed care plan (AlohaCare, HMSA QUEST, Kaiser, or UHC Community Plan, depending on enrollment) directly and in writing whether a formulary exception process exists. Because resmetirom is currently the only FDA-approved pharmacotherapy specifically indicated for MASH with fibrosis, a "no therapeutic alternative" argument in a formulary exception request has some clinical logic behind it, but approval is not guaranteed and depends on the plan's own exception criteria.
Madrigal Pharmaceuticals has described patient assistance and co-pay support programs for eligible commercially insured and uninsured patients. Exact income thresholds, co-pay caps, and program terms change and should be confirmed directly with the manufacturer's support program rather than assumed from older figures, since manufacturer assistance programs are frequently revised.
Resmetirom is an FDA-approved oral therapy for MASH with F2-F3 fibrosis, prescribable by any Hawaii-licensed physician, NP, or PA (including by telehealth), but Hawaii Medicaid does not cover it as of this writing and most commercial plans require prior authorization documenting fibrosis stage and normal-range liver enzymes before dispensing; patients should treat the FDA label as the source for clinical eligibility criteria and their specific plan as the source for coverage terms, because those two facts do not move at the same pace.
A realistic timeline
From first consultation to first dose, a workable range is roughly two to six weeks, driven mostly by three variable steps rather than by Hawaii geography:
- Getting fibrosis staging completed, if not already done (may require scheduling elastography)
- Prior authorization review by the insurer
- Specialty pharmacy shipping to a Hawaii address, which is typically a few business days once approved
Having biopsy or elastography results and recent labs ready before the first prescriber visit is the single biggest lever a patient has over this timeline; it removes the step that most often causes a mid-process delay.
Moving an existing prescription to Hawaii
Hawaii's Board of Pharmacy permits prescription transfers between pharmacies, including from an out-of-state pharmacy, for non-controlled medications like resmetirom. If both the sending and receiving pharmacy are in the same specialty network, the transfer is usually simpler. A cross-network transfer may instead require a new prescription from a Hawaii-licensed prescriber. Start a transfer at least two weeks before the current supply runs out to allow for shipping time to Hawaii, including neighbor islands.
Verification checklist: what stays true vs. what needs to be checked today
This table separates facts that are stable (federal approval status, clinical criteria) from facts that are date-sensitive and plan- or state-specific (coverage, price, PA rules). Before acting on anything in this article, re-check the right-hand items with the actual payer, pharmacy, or state board involved.
| Category | Generally stable (verify occasionally) | Date-sensitive (verify before every decision) |
|---|---|---|
| Regulatory status | FDA approval of Rezdiffra for MASH with F2-F3 fibrosis (March 2024) | Any label updates, new contraindications, or post-marketing safety changes |
| Clinical eligibility | Fibrosis stage F2-F3 required; decompensated cirrhosis is a contraindication; baseline ALT/AST threshold | Which noninvasive staging combination a specific insurer will accept as documentation |
| Prescriber authority | Non-controlled drug, prescribable by MD/DO/APRN/PA in Hawaii | Current Hawaii scope-of-practice rules for APRNs and PAs (check with the relevant licensing board) |
| Telehealth | Hawaii permits telehealth prescribing of non-controlled medications | Whether a specific out-of-state telehealth platform is currently registered to practice in Hawaii |
| Pharmacy access | Specialty pharmacy distribution model; 503A compounding is legal in Hawaii for patient-specific orders | Which specialty pharmacy is in-network for your plan; current shipping timelines to your island |
| Coverage | Rezdiffra is FDA-approved, so medical necessity is not in question when criteria are met | Hawaii Medicaid coverage status, your specific commercial plan's PA requirements and turnaround time, current manufacturer assistance program terms and eligibility thresholds |
| Cost | Resmetirom is a specialty-tier drug with a list price set by the manufacturer | The current list price, your plan's specialty co-pay tier, and any co-pay assistance cap, all of which change over time |
When to seek care sooner than a scheduled follow-up
Contact your prescriber promptly, rather than waiting for a routine follow-up, if you notice jaundice, dark urine, unusual fatigue, right upper quadrant abdominal pain, or any new symptom suggestive of liver injury while on resmetirom. These can signal a need for urgent liver enzyme testing and reassessment of whether continuing the drug is appropriate. This article does not replace an individualized dosing or monitoring plan from the prescriber who has reviewed your labs and history.
Frequently asked questions
How do I get a Rezdiffra (resmetirom) prescription in Hawaii?
What labs are needed before starting Rezdiffra (resmetirom)?
Can a telehealth provider prescribe Rezdiffra to someone in Hawaii?
Does Hawaii Medicaid cover Rezdiffra (resmetirom)?
How long does it take to get Rezdiffra after a first appointment in Hawaii?
Can I transfer my Rezdiffra prescription to a Hawaii pharmacy?
Sources and further reading
- U.S. Food and Drug Administration, Rezdiffra (resmetirom) prescribing information, approved March 2024: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217785s000lbl.pdf
Claims about the pivotal trial supporting approval, current AASLD or other liver-society practice guidance, Hawaii-specific telehealth and pharmacy statutes, exact prior authorization turnaround times by insurer, and current drug pricing were not independently verifiable against a confirmed primary source at the time this draft was prepared. These items are flagged for the editorial and medical reviewer to verify against the current FDA label, the relevant Hawaii statutes and administrative rules, and the payer in question before publication, and any unverifiable figure should be removed or replaced with sourced current information rather than published as stated here.